Ensayos clínicos

Peripheral artery disease (PAD)

Displaying 5 studies

  • Automated Non-Invasive Arterial Pressure Device in Normals and in Patients with Peripheral Arterial Disease Rochester, MN

    The purpose of this study is to determine the accuracy of an automated non-invasive arterial pressure device when assessing people with peripheral arterial disease.   The arterial pressure from each limb and calculated ABI’s from standard non-invasive arterial vascular testing verses automated non-invasive arterial device will be compared.

  • A Study of the Delivery of Yamani-15/5 Chemical Solution for Peripheral Artery Disease Jacksonville, FL

    This is a feasibility study to evaluate the impact of local delivery of Yamani-15/5 (combination of L-Lactic acid 15% and D-Gluconic acid 5%) on vascular calcification of lower extremities in patients with severe peripheral arterial disease who were deemed to have unreconstructable arterial disease and who have already been scheduled to undergo below knee or above knee amputation.

  • Ultrasound Utility in Carpal Tunnel Syndrome Scottsdale/Phoenix, AZ

    As CTS is the most commonly diagnosed compression neuropathy of the upper extremity, assessment of severity and treatment response is important crucial to determine the clinical outcomes. Currently, physical examination and overall functional status as well as pre-op electrodiagnostic (EDX) testing are important in determining patient outcome scores and assessing the treatment response. The physical properties of MN and surrounding tissue may be good biomarkers for this evaluation.

    SWE is a qualitative and quantitative method for measuring tissue stiffness. There are limited studies on using SWE for diagnosis of CTS , but other aspects of CTS, including the ...

  • Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol Rochester, MN

    This is a Phase III, placebo-controlled, double-blind, randomized study in participants with ASCVD and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to evaluate the efficacy, safety, and tolerability of subcutaneous (SC) inclisiran injection(s). The study will be a multicenter study in the United States.

  • Vascular Diseases Biorepository Rochester, MN

    The eventual goal of this study is to identify genetic and proteomic markers that may influence susceptibility to vascular diseases including peripheral arterial disease, pulmonary hypertension, carotid artery stenosis, arterial aneurysmal disease, fibromuscular dysplasia, congenital heart disease and other less common diseases that affect the blood vessels.

.

Mayo Clinic Footer